Open Innovation for the Korean Pharma Industry

May 11, 2018 By IdeaConnection

Delegates at the recently held Korean Pharma Associations Conference (KPAC) 2018 spent part of their time talking about the importance of open innovation to improve public health and for the growth of local and foreign pharmaceutical companies.

And one of the key topics was how to facilitate open innovation for new drug development.

“As research and development activities for new drugs are becoming open innovation-based ones, innovative ideas, knowledge, and know-how are being shared without boundaries,” said Lee Jung-hee, board chair of the KPBMA.

“Korea will be able to become a pharmaceutical powerhouse if the aggressive efforts of the pharma industry are combined with bold open innovation and the government’s practical support.”

Open Innovation Approaches for New Drug Development

Government and pharmaceutical experts from business, academic, research and hospital sectors who attended the conference discussed a number of ways to engage with open innovation. They included:

A patient-centered approach that would entail the involvement of the medical community from the early stages of a new drug’s development.

Research-driven hospitals that don’t just rely on in-house research but provide open platforms for open innovation.

An ecosystem where domestic and foreign pharmaceutical firms can cooperate.

Open Innovation is a Must

Choi Tae-hong, CEO of Boryung Pharmaceutical, echoed the thoughts of many when he said that open innovation was a must not an option for new drug development.

The country’s government is making growth in the pharma industry a priority and to that end will also be building an infrastructure to support AI-based drug development.

Share on      
Next Post »

Reader Comments

aids Virus killing Invest in the manufacture of biological agents.

Let's face the birth of innovation in pharmaceutical manufacturing cooperation.

Could it be the following innovative pharmaceutical candidates?

I would like to collaborate with your lab on business cooperation and research.
Modern, science is not yet capable of treating human blood viral disease.
The cure for this disease is a complete death of the virus from the blood and organs.
Chemical combinations (drugs, injections, antivirals, etc.) can not kill human blood virus at all.

The consumption of natural products naturally grown in nature must be ingested by humans.
100% virus kill (including HIV + HCV, HIV + HBV, HBV + HCV complex infection)

Food intake alone will restore normal CD-4/8, and platelet counts will recover to normal levels.
This process is the wondrous mechanism of the human body as the realm of God.

I develop this therapeutic substance and propose a collaborative research with relevant organizations around the world.

0: manufacture of viral killing substance,
0: antibody produced after complete killing of blood virus,
Weakened viral bacteria are used to produce vaccines and prevent viral viral diseases in humans.

Antibodies generated after complete killing of blood viruses,
Weakened viral live bacteria are used for vaccine production and prevention of human blood viral diseases.

Hepatitis B is a treatment guide.
In the war against the human immune system after the first virus infection
CD-4/8 immune cells, platelet counts decreased in combat with viruses.
The pain of the disease becomes worse.

The only way to treat is recovery of CD-4/8 and platelet counts due to food intake,
This is a human mechanism for "immunological conversion" of blood circulation viruses.

Self-catering food is self-healing.
It is a hydrothermal treatment liquid of natural material that grows in nature. Many raw materials are born in nature from China, India and Korea.

For national commercial approval for the manufacture of blood sputtering virus healing materials,
We propose and cooperate.

I am not interested in future meetings and papers to be announced in foreign countries.
We want to work with organizations around the world to manufacture HIV and HBV biotherapeutics and to manufacture therapeutic vaccines.

For these two projects, we propose cooperation and business cooperation research with related organizations, companies and research institutes around the world.
Collaboration is required for the progress of the collaboration process.

Please refer to three cases of blood virus cure for attachment.
Vertical infection After 45 years of hepatitis progression, the cure period was 5 months.
Horizontal infection After 33 years of hepatitis progression, the duration of the cure was 11 months.

Thank ,
Human Blood Virus Institute
Posted by E Rang Kim on July 2, 2018

Add your Comment

[LOGIN FIRST] if you're already a member.

fields are required.

Note: Your name will appear at the bottom of your comment.